Solventum Corp.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $8.33B | $8.25B | $8.20B | $8.28B | $8.28B |
| MedSurgical | — | — | $4.64B | $4.59B | $4.62B |
| Dental Solutions | — | — | $1.27B | $1.33B | $1.39B |
| Health Information Systems | — | — | $1.28B | $1.28B | $1.22B |
| Purification and Filtration | — | — | $1.01B | $1.08B | $1.06B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | $4.45B | $4.59B | $4.69B | $4.70B | — |
| Gross Margin | 53.5% | 55.6% | 57.2% | 56.7% | — |
| Operating Expenses | |||||
| Research & Development | $739.0M | $775.0M | $758.0M | $767.0M | — |
| SG&A Expense | $3.08B | $2.78B | $2.30B | $2.24B | — |
| Operating Income | $2.18B | $1.04B | $1.69B | $1.69B | — |
| Operating Margin | 26.2% | 12.6% | 20.6% | 20.5% | — |
| Interest Expense | — | — | — | — | — |
| Pretax Income | $1.71B | $605.0M | $1.67B | $1.69B | — |
| Income Tax Expense | $157.0M | $127.0M | $321.0M | $349.0M | — |
| Net Income | $1.56B | $479.0M | $1.35B | $1.34B | — |
| Net Margin | 18.7% | 5.8% | 16.4% | 16.2% | — |
| EPS (Basic) | $8.94 | $2.77 | $7.79 | $7.78 | — |
| EPS (Diluted) | $8.88 | $2.76 | $7.79 | $7.78 | — |
| Shares Outstanding (Basic) | 174.1M | 173.2M | 172.7M | 172.7M | — |
| Shares Outstanding (Diluted) | 175.3M | 173.7M | 172.7M | 172.7M | — |
| Dividends Per Share | — | — | — | — | — |